Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The company is marketing the kit under the brand name CoviFind and it can detect the infection in 15 minutes
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
It is estimated that one-third of our country’s population has some form of these disorders
The week-long campaign received a record 17.691 pledges
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
Flipkart also announced its foray into the healthcare sector through the launch of Flipkart Health+
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Subscribe To Our Newsletter & Stay Updated